肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

Keytruda针对经典霍奇金淋巴瘤的验证性3期临床试验达到了主要终点

2020-03-05 不详 MedSci原创

Keytruda经典霍奇金淋巴瘤验证性3期临床试验主要终点
关注

默克公司（MSD）的Keytruda在针对经典霍奇金淋巴瘤（cHL）的一项验证性3期临床试验中达到了主要终点，这是在Keytruda获得批准治疗此类癌症的三年后。

默克公司（MSD）的Keytruda在针对经典霍奇金淋巴瘤（cHL）的一项验证性3期临床试验中达到了主要终点，这是在Keytruda获得批准治疗此类癌症的三年后。

2017年3月，Keytruda（pembrolizumab）获得了有条件的批准，用于经过三轮或三轮以上治疗后复发的难治性cHL成人和儿童患者。这是该药物在血液系统癌症中的第一个获批的适应症，随后Keytruda获得批准用于治疗原发性纵隔B细胞淋巴瘤（一种罕见的B细胞非霍奇金淋巴瘤）。

Keytruda针对cHL的获批是基于KEYNOTE-087 2期试验的结果，最近的3期KEYNOTE-204试验进一步证实了该免疫抑制剂对血液癌症的治疗作用。

该试验将Keytruda与Seattle Genetic的抗体-药物偶联物Adcetris进行了比较，后者是复发和难治性淋巴瘤的标准治疗方法。根据独立数据监控委员会的中期审查结果显示，默克的药物在无进展生存期（PFS）方面胜过Adcetris。

根据GlobalData的预测，Keytruda的销量提升主要归因于非小细胞肺癌，该领域有望帮助PD-1抑制剂在2025年达到225亿美元的销售额。

原始出处：


本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1951221, encodeId=785719512210e, content=<a href='/topic/show?id=2d38101548e4' target=_blank style='color:#2F92EE;'>#验证性3期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101548, encryptionId=2d38101548e4, topicName=验证性3期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Sat Jun 20 16:48:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996970, encodeId=964e19969e0f6, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sun Mar 15 17:48:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911249, encodeId=6284191124954, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1289, encryptionId=18171289d6, topicName=3期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Fri May 29 14:48:00 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595515, encodeId=6f8a1595515ff, content=<a href='/topic/show?id=371912932d' target=_blank style='color:#2F92EE;'>#3期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1293, encryptionId=371912932d, topicName=3期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79cd18252620, createdName=slcumt, createdTime=Sat Mar 07 09:48:00 CST 2020, time=2020-03-07, status=1, ipAttribution=)]
    2020-06-20 nakerunner

    #验证性3期临床试验#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1951221, encodeId=785719512210e, content=<a href='/topic/show?id=2d38101548e4' target=_blank style='color:#2F92EE;'>#验证性3期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101548, encryptionId=2d38101548e4, topicName=验证性3期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Sat Jun 20 16:48:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996970, encodeId=964e19969e0f6, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sun Mar 15 17:48:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911249, encodeId=6284191124954, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1289, encryptionId=18171289d6, topicName=3期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Fri May 29 14:48:00 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595515, encodeId=6f8a1595515ff, content=<a href='/topic/show?id=371912932d' target=_blank style='color:#2F92EE;'>#3期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1293, encryptionId=371912932d, topicName=3期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79cd18252620, createdName=slcumt, createdTime=Sat Mar 07 09:48:00 CST 2020, time=2020-03-07, status=1, ipAttribution=)]
    2020-03-15 zhangj7108

    #主要终点#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1951221, encodeId=785719512210e, content=<a href='/topic/show?id=2d38101548e4' target=_blank style='color:#2F92EE;'>#验证性3期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101548, encryptionId=2d38101548e4, topicName=验证性3期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Sat Jun 20 16:48:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996970, encodeId=964e19969e0f6, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sun Mar 15 17:48:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911249, encodeId=6284191124954, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1289, encryptionId=18171289d6, topicName=3期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Fri May 29 14:48:00 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595515, encodeId=6f8a1595515ff, content=<a href='/topic/show?id=371912932d' target=_blank style='color:#2F92EE;'>#3期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1293, encryptionId=371912932d, topicName=3期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79cd18252620, createdName=slcumt, createdTime=Sat Mar 07 09:48:00 CST 2020, time=2020-03-07, status=1, ipAttribution=)]
    2020-05-29 andy2087

    #3期临床#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1951221, encodeId=785719512210e, content=<a href='/topic/show?id=2d38101548e4' target=_blank style='color:#2F92EE;'>#验证性3期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=101548, encryptionId=2d38101548e4, topicName=验证性3期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0cd7162, createdName=nakerunner, createdTime=Sat Jun 20 16:48:00 CST 2020, time=2020-06-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1996970, encodeId=964e19969e0f6, content=<a href='/topic/show?id=b706232e831' target=_blank style='color:#2F92EE;'>#主要终点#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=23278, encryptionId=b706232e831, topicName=主要终点)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7387164, createdName=zhangj7108, createdTime=Sun Mar 15 17:48:00 CST 2020, time=2020-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1911249, encodeId=6284191124954, content=<a href='/topic/show?id=18171289d6' target=_blank style='color:#2F92EE;'>#3期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1289, encryptionId=18171289d6, topicName=3期临床)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d275294, createdName=andy2087, createdTime=Fri May 29 14:48:00 CST 2020, time=2020-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1595515, encodeId=6f8a1595515ff, content=<a href='/topic/show?id=371912932d' target=_blank style='color:#2F92EE;'>#3期临床试验#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1293, encryptionId=371912932d, topicName=3期临床试验)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79cd18252620, createdName=slcumt, createdTime=Sat Mar 07 09:48:00 CST 2020, time=2020-03-07, status=1, ipAttribution=)]
    2020-03-07 slcumt

    #3期临床试验#

    0

相关资讯

默克的Keytruda成为美国批准用于治疗非肌肉浸润性膀胱癌的抗PD-1治疗药物

美国食品药物管理局于周三批准了默克的Keytruda（pembrolizumab），用于对卡介苗（BCG）不应答、高风险的、有或无乳头状瘤、不适合或已决定不进行膀胱切除术的非肌层浸润性膀胱癌（NMIBC）原位癌（CIS）患者。

英国NICE拒绝将PD-1单抗Keytruda，用于转移或复发的头颈部鳞状细胞癌

英国国立卫生研究院（NICE）已发布新指南草案，不建议将默沙东的PD-1单抗Keytruda（pembrolizumab）用于未经治疗的转移性或不可切除的复发性头颈部鳞状细胞癌（HNSCC）。

默沙东宣布PD-1单抗Keytruda治疗三阴性乳腺癌的III期临床成功

默沙东MSD宣布，在三阴性乳腺癌试验中，将其重磅炸弹PD-1单抗Keytruda（pembrolizumab）联合化疗后，可显着延长患者无进展生存期（PFS）。

FDA专家组投票赞成，批准Keytruda治疗难治性膀胱癌

在FDA专家小组的投票之后，默克（Merck）的检查点抑制剂PD-1单抗Keytruda在美国获批了新的适应症--早期膀胱癌的治疗。

NSCLC一线治疗：LAG-3抗体显著增强Keytruda的疗效，ORR达到47%！

2月19日，Immutep公司宣布其可溶性LAG-3融合蛋白eftilagimod alpha（efti，又名IMP321），与默沙东（MSD）公司的重磅PD-1抑制剂Keytruda联用，在2期临床试验中获得积极中期结果。在一线治疗非小细胞肺癌（NSCLC）患者时，这一组合疗法达到47%的总缓解率（ORR）。而如果不筛选PD-L1表达水平高的患者，Keytruda单药疗法治疗NSCLC患者的缓解

默沙东的Keytruda治疗小细胞肺癌的III期临床，未能明显改善患者的总体生存率

来自III期KEYNOTE-604试验的最新数据显示，默沙东的PD-1单抗Keytruda（派姆单抗）的结果好坏参半。与单独化疗相比，Keytruda联合化疗用作一线治疗可显着改善小细胞肺癌（SCLC）患者的无进展生存期（PFS）。